An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Recruiting now Phase 2 NCT07449702
Run by Oruka Therapeutics, Inc. · for 18 and older · All sexes
What this study is about
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Who can join (things the study team will check)
✅ You may be able to join if…
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
🚫 You may not be able to join if…
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
Where this trial is running
- Oruka Therapeutics Investigative Site, Fountain Valley, California, United States
- Oruka Therapeutics Investigative Site, Los Angeles, California, United States
- Oruka Therapeutics Investigative Site, San Diego, California, United States
- Oruka Therapeutics Investigative Site, Santa Ana, California, United States
- Oruka Therapeutics Investigative Site, Santa Monica, California, United States
- Oruka Therapeutics Investigative Site, Cromwell, Connecticut, United States
- Oruka Therapeutics Investigative Site, Miami, Florida, United States
- Oruka Therapeutics Investigative Site, Rolling Meadows, Illinois, United States
- Oruka Therapeutics Investigative Site, Bowling Green, Kentucky, United States
- Oruka Therapeutics Investigative Site, Rockville, Maryland, United States
- Oruka Therapeutics Investigative Site, Boston, Massachusetts, United States
- Oruka Therapeutics Investigative Site, Detroit, Michigan, United States
+ 12 more sites.
Who to contact
Oruka Clinical Trials Information · 781-560-0299 · clinicaltrials@orukatx.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07449702.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.